Kaiser Luana Antonia, Kupec Tomas, Najjari Laila, Stickeler Elmar, Wittenborn Julia
Department of Gynecology and Obstetrics, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.
Diagnostics (Basel). 2023 Mar 11;13(6):1066. doi: 10.3390/diagnostics13061066.
This study aims to investigate whether specific characteristics of the patient group with ASC-H (PAP III-p) findings increase the likelihood of clinically significant disease (CIN2+), offering implications for risk-adapted clinical management.
225 patients with an ASC-H smear presenting to our colposcopy unit between 2014 and 2021 were identified and examined retrospectively. A total of 203 patients were included in the cross-sectional study using multivariate logistic regression.
Of the 12 variables that entered the regression model, transformation zone ( = 0.045) and HPV infection ( = 0.005) contributed significantly to predicting CIN2+. A T3 transformation zone had a protective effect, reducing the likelihood of significant pathology. Infection with HPV high risk (non 16/18) or HPV high risk (16/18), on the contrary, increased the likelihood of CIN2+ four times and seven times, respectively, compared to the lower-risk category.
A differential approach in the workup of ASC-H cytology is advisable. Younger, premenopausal patients with positive HPV high-risk findings are at a significantly higher risk for CIN2+ lesions than older postmenopausal women with negative high-risk HPV test results. As the risk increases from HPV high-risk non 16/18 to HPV 16/18 infections, using HPV PCR testing is advisable.
本研究旨在调查具有非典型鳞状细胞不排除高度病变(PAP III-p)结果的患者群体的特定特征是否会增加临床显著疾病(CIN2+)的可能性,为风险适应性临床管理提供启示。
确定并回顾性检查了2014年至2021年间到我们阴道镜检查科室就诊的225例非典型鳞状细胞不排除高度病变涂片患者。使用多因素逻辑回归对203例患者进行横断面研究。
进入回归模型的12个变量中,转化区(=0.045)和人乳头瘤病毒感染(=0.005)对预测CIN2+有显著贡献。T3转化区具有保护作用,可降低显著病理的可能性。相反,与低风险类别相比,高危型人乳头瘤病毒(非16/18型)或高危型人乳头瘤病毒(16/18型)感染使CIN2+的可能性分别增加四倍和七倍。
对非典型鳞状细胞不排除高度病变细胞学检查采用差异化方法是可取的。高危型人乳头瘤病毒检测结果呈阳性的年轻绝经前患者患CIN2+病变的风险明显高于高危型人乳头瘤病毒检测结果呈阴性的老年绝经后女性。随着风险从高危型人乳头瘤病毒非16/18型感染增加到高危型人乳头瘤病毒16/18型感染,建议使用人乳头瘤病毒聚合酶链反应检测。